VYN202 induced a dose-dependent increase in the target engagement biomarker HEXIM-1 1 with a maximal effect observed at 0.5mg to 1.0 mg QD. For more information on the Phase 1a trial results, please ...
The U.S. Food and Drug Administration on Friday approved the first prescription medicine for obstructive sleep apnea: the ...
Luigi Mangione, 26, was formally charged last week by the Manhattan district attorney with multiple counts of murder, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback